By Connor Hart
Vaxart appointed Jeroen Grasman as its chief financial officer, effective May 19.
Grasman will succeed Phillip Lee, who is resigning from the top finance position for personal reasons, the clinical-stage biotechnology company said Tuesday.
Lee will remain with the company as a non-executive employee through June 1 in order to assist with the transition.
Grasman has more than 20 years of financial leadership experience in the biotechnology industry, Vaxart said. He most recently served as CFO of AltruBio, a private clinical-stage biotech company. Prior, he held leadership roles at PACT Pharma and Intarcia Therapeutics.
Vaxart disclosed the CFO succession as it posted a net loss of $15.6 million, or 7 cents a share in the first quarter, compared with a loss of $24.4 million, or 14 cents a share, a year earlier.
Revenue increased to $20.9 million from $2.2 million.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
May 13, 2025 16:21 ET (20:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。